Can the use of the PPAR-gamma agonist rosiglitazon reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in HIV-associated lipodystrophy syndrome?
Completed
- Conditions
- HIV+ patients, with lipodystrophy (based on fat distribution disturbances), not using d4T nor a protease inhibitor.
- Registration Number
- NL-OMON25981
- Lead Sponsor
- Academic medical centre, Dept of endocrinology and metabolism, F5-170, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1. Male;
2. age>18 years;
Exclusion Criteria
1. Active hepatitis;
2. ALAT/ASAT>2.5x above normal level;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method